STOCK TITAN

CytoDyn (CYDY) Stock News, Sep 29, 2020

CYDY OTC

CytoDyn Inc. reports developments for leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor. The company is a clinical-stage oncology issuer focused on CCR5 biology in difficult-to-treat cancers, including metastatic triple-negative breast cancer and metastatic colorectal cancer.

Recurring news includes clinical and translational data presentations, Phase 2 colorectal cancer study updates, expanded access activity for triple-negative breast cancer, and preclinical work in glioblastoma. Company updates also cover financing actions used to support leronlimab development and corporate webcasts addressing scientific, operational, clinical, and financial progress.

Rhea-AI Summary

CytoDyn Inc. (OTC.QB: CYDY) announces its 2020 Virtual Annual Meeting of Stockholders, scheduled for September 30, 2020, at 9:30 am PT. Due to health concerns from the coronavirus pandemic, in-person attendance is not allowed. Stockholders can log in to participate via the provided webcast link, and questions can be submitted online during the meeting with the passcode CYDY2020. Dr. Nader Pourhassan, CEO, will present a company overview post-business session, with materials available on the company website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.41%
Tags
conferences

FAQ

What is the current stock price of CytoDyn (CYDY)?

CytoDyn (CYDY) last closed at $0.2220.

What is the market cap of CytoDyn (CYDY)?

The market cap of CytoDyn (CYDY) is approximately $326.2M.